The pharmaceutical community is buzzing with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 receptor that’s showing significant potential in clinical trials for treating obesity. Unlike some existing weight loss approaches, retatrutide appears to provide a more substantial loss in body size and benefit metabolic markers, particu